

# Patrick J Hensley

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6271004/publications.pdf>

Version: 2024-02-01

39  
papers

593  
citations

759055

12  
h-index

642610

23  
g-index

40  
all docs

40  
docs citations

40  
times ranked

1000  
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting caspases in cancer therapeutics. <i>Biological Chemistry</i> , 2013, 394, 831-843.	1.2	134
2	PARP-1 regulates epithelial-mesenchymal transition (EMT) in prostate tumorigenesis. <i>Carcinogenesis</i> , 2014, 35, 2592-2601.	1.3	58
3	TGF $\beta$ 2 receptor I inhibitor enhances response to enzalutamide in a preclinical model of advanced prostate cancer. <i>Prostate</i> , 2019, 79, 31-43.	1.2	46
4	Predictive value of epithelial-mesenchymal transition (EMT) signature and PARP-1 in prostate cancer radioresistance. <i>Prostate</i> , 2017, 77, 1583-1591.	1.2	36
5	Novel Pharmacologic Targeting of Tight Junctions and Focal Adhesions in Prostate Cancer Cells. <i>PLoS ONE</i> , 2014, 9, e86238.	1.1	32
6	Prostate tumor neuroendocrine differentiation via EMT: The road less traveled. <i>Asian Journal of Urology</i> , 2019, 6, 82-90.	0.5	32
7	Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guérin: Implications for Clinical Trial Design. <i>Journal of Urology</i> , 2021, 205, 1612-1621.	0.2	31
8	Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin. <i>European Urology Oncology</i> , 2022, 5, 84-91.	2.6	24
9	Management, Surveillance Patterns, and Costs Associated With Low-Grade Papillary Stage Ta Non-muscle-Invasive Bladder Cancer Among Older Adults, 2004-2013. <i>JAMA Network Open</i> , 2022, 5, e223050.	2.8	23
10	Association of epithelial-mesenchymal transition and nuclear cofilin with advanced urothelial cancer. <i>Human Pathology</i> , 2016, 57, 68-77.	1.1	22
11	Contemporary Staging for Muscle-Invasive Bladder Cancer: Accuracy and Limitations. <i>European Urology Oncology</i> , 2022, 5, 403-411.	2.6	17
12	Examining and Understanding Value: The Impact of Preoperative Characteristics, Intraoperative Variables, and Postoperative Complications on Cost of Robot-Assisted Laparoscopic Radical Prostatectomy. <i>Journal of Endourology</i> , 2019, 33, 541-548.	1.1	15
13	Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy. <i>Journal of Urology</i> , 2021, 206, 577-585.	0.2	14
14	Primary Upper Urinary Tract Small Cell Carcinoma: A Case Series and Literature Review. <i>Journal of Endourology Case Reports</i> , 2017, 3, 165-168.	0.3	13
15	Evaluation of Glutaminase Expression in Prostate Adenocarcinoma and Correlation with Clinicopathologic Parameters. <i>Cancers</i> , 2021, 13, 2157.	1.7	12
16	Evaluating post radical prostatectomy mechanisms of early continence. <i>Prostate</i> , 2022, 82, 1186-1195.	1.2	10
17	Predictive value of phenotypic signatures of bladder cancer response to cisplatin-based neoadjuvant chemotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 572.e1-572.e11.	0.8	9
18	Optimization of Patient Selection for Neoadjuvant Chemotherapy in Muscle-invasive Urothelial Carcinoma of the Bladder. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e851-e858.	0.9	8

#	ARTICLE	IF	CITATIONS
19	Reduced-dose bacillus Calmette-Guérin (BCG) in an era of BCG shortage: real-world experience from a tertiary cancer centre. <i>BJU International</i> , 2022, 130, 323-330.	1.3	8
20	Progression of Disease after Bacillus Calmette-Guérin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. <i>Journal of Urology</i> , 2021, 206, 1258-1267.	0.2	7
21	Role of Lymphadenectomy during Radical Cystectomy for Nonmuscle-Invasive Bladder Cancer: Results from a Multi-Institutional Experience. <i>Journal of Urology</i> , 2022, 207, 551-558.	0.2	7
22	All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Guérin Response in High-Grade Ta Tumors. <i>Journal of Urology</i> , 2022, 208, 284-291.	0.2	7
23	Time interval from transurethral resection of bladder tumour to bacille Calmette-Guérin induction does not impact therapeutic response. <i>BJU International</i> , 2021, 128, 634-641.	1.3	5
24	Impact of sex on response to BCG in non-muscle invasive bladder cancer patients: a contemporary review from a tertiary care center. <i>World Journal of Urology</i> , 2021, 39, 4143-4149.	1.2	5
25	Efficacy and safety of alvimopan use in benign urinary tract reconstruction. <i>International Urology and Nephrology</i> , 2021, 53, 77-82.	0.6	3
26	Germline Mutations in African American Men With Prostate Cancer: Incidence, Implications and Diagnostic Disparities. <i>Urology</i> , 2022, 163, 148-155.	0.5	3
27	Clinicopathological analysis and outcomes of inflammatory myofibroblastic tumours of the urinary bladder. <i>BJU International</i> , 2022, 130, 604-610.	1.3	3
28	Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer. <i>BJU International</i> , 2021, 128, 568-574.	1.3	2
29	Examining and Understanding Value: The Cost of Preoperative Characteristics, Intraoperative Variables and Postoperative Complications of Minimally Invasive Partial Nephrectomy. <i>Urology Practice</i> , 2019, 6, 215-221.	0.2	2
30	Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guérin Therapy Outcomes. <i>European Urology Oncology</i> , 2021, , .	2.6	1
31	High-intensity local treatment of clinical node-positive urothelial carcinoma of the bladder alongside systemic chemotherapy improves overall survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 62.e1-62.e11.	0.8	1
32	Should Patients With Non-muscle-invasive Bladder Cancer Discontinue Fibrin Clot Inhibitors During BCG?. <i>BJU International</i> , 2021, , .	1.3	1
33	Surgical management of pediatric renal masses: surgeon subspecialty practice patterns. <i>Canadian Journal of Urology</i> , 2020, 27, 10329-10335.	0.0	1
34	Demographic disparities of penile cancer in Appalachian Kentucky. <i>Canadian Journal of Urology</i> , 2021, 28, 10713-10718.	0.0	1
35	International Publication Patterns on Operative Management of Wilms Tumor: A Review by Surgeon Specialty and Surgical Modality. <i>Urology</i> , 2020, 140, 132-137.	0.5	0
36	Reply by Authors. <i>Journal of Urology</i> , 2021, 205, 1620-1621.	0.2	0

#	ARTICLE	IF	CITATIONS
37	Reply by Authors. Journal of Urology, 2021, 206, 1267.	0.2	0
38	Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: Implications for Clinical Trial Design. Reply.. Journal of Urology, 2021, , 101097JU00000000000002238.	0.2	0
39	Operative duration and short term morbidity and mortality following radical cystectomy with urinary diversion.. Canadian Journal of Urology, 2022, 29, 11087-11094.	0.0	0